The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Interleukin 2 receptor antagonists for kidney transplant recipients
Open accessAbstract
BACKGROUND: Interleukin 2 receptor antagonists (IL2Ra) are used as induction therapy for prophylaxis against acute rejection in kidney transplant recipients. Use of IL2Ra has increased steadily since their introduction, but the proportion of new transplant recipients receiving IL2Ra differs around the globe, with 27% of new kidney transplant recipients in the United States, and 70% in Australasia receiving IL2Ra in 2007. OBJECTIVES: To systematically identify and summarise the effects of using an IL2Ra, as an addition to standard therapy, or as an alternative to another immunosuppressive induction strategy. SEARCH STRATEGY: We searched the Cochrane Renal Group's specialised register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE to identify new records, and authors of included reports were contacted for clarification where necessary. SELECTION CRITERIA: Randomised controlled trials (RCTs) in all languages comparing IL2Ra to placebo, no treatment, other IL2Ra or other antibody therapy. DATA COLLECTION AND ANALYSIS: Data was extracted and assessed independently by two authors, with differences resolved by discussion. Dichotomous outcomes are reported as relative risk (RR) and continuous outcomes as mean difference (MD) with 95% confidence intervals (CI). MAIN RESULTS: We included 71 studies (306 reports, 10,537 participants). Where IL2Ra were compared with placebo (32 studies; 5,784 patients) graft loss including death with a functioning graft was reduced by 25% at six months (16 studies: RR 0.75, 95% CI 0.58 to 0.98) and one year (24 studies: RR 0.75, 95% CI 0.62 to 0.90), but not beyond this. At one year biopsy-proven acute rejection was reduced by 28% (14 studies: RR 0.72, 95% CI 0.64 to 0.81), and there was a 19% reduction in CMV disease (13 studies: RR 0.81, 95% CI 0.68 to 0.97). There was a 64% reduction in early malignancy within six months (8 studies: RR 0.36, 95% CI 0.15 to 0.86), and creatinine was lower (7 studies: MD -8.18 micromol/L 95% CI -14.28 to -2.09) but these differences were not sustained.When IL2Ra were compared to ATG (16 studies, 2211 participants), there was no difference in graft loss at any time point, or for acute rejection diagnosed clinically, but the was benefit of ATG therapy over IL2Ra for biopsy-proven acute rejection at one year (8 studies:, RR 1.30 95% CI 1.01 to 1.67), but at the cost of a 75% increase in malignancy (7 studies: RR 0.25 95% CI 0.07 to 0.87) and a 32% increase in CMV disease (13 studies: RR 0.68 95% CI 0.50 to 0.93). Serum creatinine was significantly lower for IL2Ra treated patients at six months (4 studies: MD -11.20 micromol/L 95% CI -19.94 to -2.09). ATG patients experienced significantly more fever, cytokine release syndrome and other adverse reactions to drug administration and more leucopenia but not thrombocytopenia. There were no significant differences in outcomes according to cyclosporine or tacrolimus use, azathioprine or mycophenolate, or to the study populations baseline risk for acute rejection. There was no evidence that effects were different according to whether equine or rabbit ATG was used. AUTHORS' CONCLUSIONS: Given a 38% risk of rejection, per 100 recipients compared with no treatment, nine recipients would need treatment with IL2Ra to prevent one recipient having rejection, 42 to prevent one graft loss, and 38 to prevent one having CMV disease over the first year post-transplantation. Compared with ATG treatment, ATG may prevent some experiencing acute rejection, but 16 recipients would need IL2Ra to prevent one having CMV, but 58 would need IL2Ra to prevent one having malignancy. There are no apparent differences between basiliximab and daclizumab. IL2Ra are as effective as other antibody therapies and with significantly fewer side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Improving the Quality of Reporting of Randomized Controlled Trials: The CONSORT Statement
Begg, C. (1996) · JAMA · doi:10.1001/jama.1996.03540080059030 · Cited by 3,127
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,401
Systematic Reviews: Identifying relevant studies for systematic reviews
Dickersin, K., Scherer, R., & Lefebvre, C. (1994) · BMJ · doi:10.1136/bmj.309.6964.1286 · Cited by 2,256
Deeks, J. J., Altman, D. G., & Bradburn, M. J. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch15 · Cited by 2,163
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, Š., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J. M., Frei, U., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067411 · Cited by 1,810
Systematic Reviews in Health Care: Meta‐Analysis in Context
(2001) · doi:10.1002/9780470693926 · Cited by 1,693
Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation
Vincenti, F., Kirkman, R., Light, S., Bumgardner, G., Pescovitz, M., Halloran, P., Neylan, J., Wilkinson, A., Ekberg, H., Gaston, R., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801153380304 · Cited by 864
Strategies to Improve Long-Term Outcomes after Renal Transplantation
Pascual, M., Theruvath, T., Kawai, T., Tolkoff-Rubin, N., & Cosimi, A. B. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011295 · Cited by 844
How to identify randomized controlled trials in MEDLINE: ten years on.
Glanville, J., Lefebvre, C., Miles, J. N. V., & Camosso‐Stefinovic, J. (2006) · Europe PMC (PubMed Central) · Cited by 833
Nashan, B., Moore, R., Amlot, P., Schmidt, A.-G., Abeywickrama, K., & Soulillou, J.-P. (1997) · The Lancet · doi:10.1016/s0140-6736(97)09278-7 · Cited by 749
Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplantation
Brennan, D. C., Daller, J. A., Lake, K. D., Cibrik, D., & Del Castillo, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060068 · Cited by 742
Cha, M., Eastwaad, S., Hartan, R., Maher, D., Olkin, I., Pitkin, R., Rennie, D., Schulz, K. F., Simel, D. L., & Straup, D. F. (1996) · Cited by 737
Lefebvre, C., Manheimer, E., & Glanville, J. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch6 · Cited by 559
Kahan, B. D., Rajagopalan, P. R., & Hall, M. (1999) · Transplantation · doi:10.1097/00007890-199901270-00016 · Cited by 476
Immunosuppressive strategies in transplantation
Denton, M. D., Magee, C. C., & Sayegh, M. H. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07493-5 · Cited by 449
Flechner, S. M., Goldfarb, D., Modlin, C., Feng, J., Krishnamurthi, V., Mastroianni, B., Savas, K., Cook, D. J., & Novick, A. C. (2002) · Transplantation · doi:10.1097/00007890-200210270-00002 · Cited by 375
Vincenti, F., Schena, F. P., Paraskevas, S., Hauser, I. A., Walker, R. G., & Grinyo, J. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.02057.x · Cited by 316
REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1
Nashan, B., Light, S., Hardie, I. R., Lin, A., & Johnson, J. R. (1999) · Transplantation · doi:10.1097/00007890-199901150-00019 · Cited by 302
Flechner, S. M., Kurian, S. M., Solez, K., Cook, D. J., Burke, J. T., Rollin, H., Hammond, J. A., Whisenant, T., Lanigan, C. M., Head, S. R., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00627.x · Cited by 281
Soulillou, J.-P., Cantarovich, D., Le Mauff, B., Giral, M., Robillard, N., Hourmant, M., Hirn, M., & Jacques, Y. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221702 · Cited by 267
B-Cell–Depleting Induction Therapy and Acute Cellular Rejection
Clatworthy, M. R., Watson, C. J. E., Plotnek, G., Bardsley, V., Chaudhry, A. N., Bradley, J. A., & Smith, K. G. C. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0808481 · Cited by 257
Vitko, S., Tedesco, H., Eris, J., Pascual, J., Whelchel, J., Magee, J. C., Campbell, S., Civati, G., Bourbigot, B., Filho, G. A., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00389.x · Cited by 254
Rostaing, L., Cantarovich, D., Mourad, G., Budde, K., Rigotti, P., Mariat, C., Margreiter, R., Capdevilla, L., Lang, P., Vialtel, P., et al. (2005) · Transplantation · doi:10.1097/01.tp.0000154915.20524.0a · Cited by 249
Webster, A. C., Playford, E. G., Higgins, G., Chapman, J. R., & Craig, J. C. (2004) · Transplantation · doi:10.1097/01.tp.0000109643.32659.c4 · Cited by 229
Self-citationCiancio, G., Burke, G. W., Gaynor, J. J., Carreno, M. R., Cirocco, R. E., Mathew, J. M., Mattiazzi, A., Cordovilla, T., Roth, D., Kupin, W., et al. (2005) · Transplantation · doi:10.1097/01.tp.0000165847.05787.08 · Cited by 220
Shah, S., Grant, D., McGilvray, I. D., Greig, P., Selzner, M., Lilly, L., Girgrah, N., Levy, G., & Cattral, M. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01601.x · Cited by 201
Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients
Noe[Combining Diaeresis]l, C., Abramowicz, D., Durand, D., Mourad, G., Lang, P., Kessler, M. G. A., Charpentier, B., Touchard, G., Berthoux, F. C., Merville, P., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008101037 · Cited by 199
A Randomized, Prospective Trial of Rituximab for Acute Rejection in Pediatric Renal Transplantation
Zarkhin, V., Li, L., Kambham, N., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02411.x · Cited by 147
Immunosuppressive agents in organ transplantation: past, present, and future.
Hong, J. C., & Kahan, B. D. (2000) · PubMed · Cited by 145
Flechner, S. M., Goldfarb, D. A., Solez, K., Modlin, C. S., Mastroianni, B., Savas, K., Babineau, D. C., Kurian, S. M., Salomon, D. R., Novick, A. C., et al. (2007) · Transplantation · doi:10.1097/01.tp.0000258586.52777.4c · Cited by 144
ter Meulen, C. G., van Riemsdijk, I. C., Hené, R. J., Christiaans, M. H. L., Borm, G. F., van Gelder, T., Hilbrands, L. B., Weimar, W. W., & Hoitsma, A. J. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00419.x · Cited by 128
Ekberg, H., Bernasconi, C., Noeldeke, J., Yussim, A., Mjörnstedt, L., Erken, U., Ketteler, M., & Navrátil, P. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp778 · Cited by 123
Long-Term Results of Rabbit Antithymocyte Globulin and Basiliximab Induction
Brennan, D. C., & Schnitzler, M. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0805714 · Cited by 117
Vitko, S., Klinger, M., Salmela, K. T., Włodarczyk, Z., Tydén, G., Senatorski, G., Ostrowski, M., Fauchald, P., Kokot, F., Stefoni, S., et al. (2005) · Transplantation · doi:10.1097/01.tp.0000188300.26762.74 · Cited by 113
Ciancio, G., Burke, G. W., Gaynor, J. J., Roth, D., Kupin, W. L., Rosen, A. L., Cordovilla, T., Tueros, L., Herrada, E., & Miller, J. (2007) · Clinical Transplantation · doi:10.1111/j.1399-0012.2007.00774.x · Cited by 106
Balancing benefits and harms in health care
Cuervo, L. G., & Clarke, M. J. (2003) · BMJ · doi:10.1136/bmj.327.7406.65 · Cited by 105
Junior, H. T. S., Vitko, S., Pascual, J., Eris, J., Magee, J. C., Whelchel, J., Civati, G., Campbell, S. B., Alves-Filho, G., Bourbigot, B., et al. (2006) · Transplant International · doi:10.1111/j.1432-2277.2006.00414.x · Cited by 102
Kumar, M. S. A., Heifets, M., Moritz, M. J., Saeed, M. I., Khan, S., Fyfe, B. S., Sustento-Riodeca, N., Daniel, J. S., & Kumar, A. (2006) · Transplantation · doi:10.1097/01.tp.0000203558.34739.c6 · Cited by 92
Kovarik, J. M., Kahan, B. D., Rajagopalan, P. R., et al. (1999) · Transplantation · doi:10.1097/00007890-199911150-00012 · Cited by 92
Grenda, R., Watson, A. R., Vondrák, K., Webb, N. J. A., Beattie, J., Fitzpatrick, M., Saleem, M. A., Trompeter, R. S., Milford, D. V., Moghal, N. E., et al. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01367.x · Cited by 81
Hesselink, D. A., Ngyuen, H., Wabbijn, M., Gregoor, P. J. H. S., Steyerberg, E. W., van Riemsdijk, I. C., Weimar, W. W., & van Gelder, T. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2003.01882.x · Cited by 81
Hamdy, A. F. A., El‐Agroudy, A. E., Bakr, M. A., et al. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01064.x · Cited by 71
Painter, P., Topp, K. S., Krasnoff, J. B., Adey, D., Strasner, A., Tomlanovich, S. J., & Stock, P. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00038.x · Cited by 68
Enhancing transplant patients' adherence to medication therapy
Chisholm, M. A. (2002) · Clinical Transplantation · doi:10.1034/j.1399-0012.2002.00104.x · Cited by 59
Kumar, M. S. A., Xiao, S., Fyfe, B. S., Sierka, D., Heifets, M., Moritz, M. J., Saeed, M. I., & Kumar, A. (2004) · Clinical Transplantation · doi:10.1111/j.1399-0012.2004.00298.x · Cited by 58
Obtaining Individual Patient Data from Randomised Controlled Trials
Clarke, M. J., & Stewart, L. A. (2001) · Wiley eBooks · doi:10.1002/9780470693926.ch6 · Cited by 57
Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab
Pascual, J. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.9.1756 · Cited by 50
Hernández, D., Miquel, R., Porrini, E., Fernández, A. M., González‐Posada, J. M., Hortal, L., Checa, M. D., Rodríguez, A., García, J. J., Rufino, M., et al. (2007) · Transplantation · doi:10.1097/01.tp.0000282872.17024.b7 · Cited by 49
Krämer, B. K., Neumayer, H. H., Stahl, R. K., et al. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.09.026 · Cited by 46
Montagnino, G., Sandrini, S., Iorio, B., Schena, F. P., Carmellini, M., Rigotti, P., Cossu, M., Altieri, P., Salvadori, M., Stefoni, S., et al. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm621 · Cited by 44
Gelens, M. A. C. J., Christiaans, M. H. L., van Heurn, E. L. W., van den Berg-Loonen, E. M., Peutz‐Kootstra, C. J., & van Hooff, J. P. (2006) · Transplantation · doi:10.1097/01.tp.0000232688.76018.19 · Cited by 42
Maluf, D. G., Fisher, R. A., Maroney, T. P., COTTERELL, A. H., Fulcher, A. S., Tisnado, J., Contos, M. J., Luketic, V. A., Stravitz, R. T., Shiffman, M. L., et al. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00041.x · Cited by 39
Interleukin 2 receptor antagonists for kidney transplant recipients
Webster, A. C., Playford, E. G., Higgins, G. Y., Chapman, J. R., & Craig, J. C. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003897.pub2 · Cited by 35
Self-citationPersonal dialysis capacity (PDCTM) test: a multicentre clinical study
Biesen, W. V., Carlsson, O., Bergia, R., Brauner, M., Christensson, A. G., Genestier, S., Haag–Weber, M., Heaf, J. G., Joffe, P., Johansson, A.-C., et al. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg146 · Cited by 34
Martínez-Mier, G., Méndez-López, M. T., Budar-Fernández, L. F., Estrada‐Oros, J., Franco‐Abaroa, R., George‐Micelli, E., Rios‐Martinez, L., & Méndez-Machado, G. F. (2006) · Transplantation · doi:10.1097/01.tp.0000235823.09788.f6 · Cited by 30
Nematalla, A. H., Bakr, M. A., Gheith, O. A. A., El‐Agroudy, A. E., El-Shahawy, E.-M. L., & Aghoneim, M. (2007) · PubMed · Cited by 29
Role of Anti???Interleukin-2 Receptor Antibodies in Kidney Transplantation
Cibrik, D. M., Kaplan, B. E., & Meier‐Kriesche, H. (2001) · BioDrugs · doi:10.2165/00063030-200115100-00003 · Cited by 28
Montagnino, G., Sandrini, S., Casciani, C., Schena, F. P., Carmellini, M., Civati, G., Rigotti, P., Cossu, M., Altieri, P., Salvadori, M., et al. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.11.033 · Cited by 25
Activated Protein C Reduces Graft Neutrophil Activation in Clinical Renal Transplantation
Turunen, A., Fernández, J. A., Lindgren, L., Salmela, K. T., Kyllönen, L., Mäkisalo, H., Griffin, J. H., Siitonen, S. M., Petäjäa, J., & Pesonen, E. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.00994.x · Cited by 20
Bączkowska, T., Perkowska‐Ptasińska, A., Sadowska, A., Lewandowski, Z., Nowacka-Cieciura, E., Cieciura, T., Pazik, J., Lewandowska, D., Mróz, A., Urbanowicz, A., et al. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2005.01.030 · Cited by 19
Kim, M. J., Tsinalis, D., Franz, S., Binet, I., Gürke, L., Mihatsch, M. J., Steiger, J. U., Thiel, G. T., & Dickenmann, M. (2008) · PubMed · Cited by 12
Preliminary results of a prospective randomized study of basiliximab in kidney transplantation
Pisani, F., Buonomo, O. C., Iaria, G., Tisone, G., Mazzarella, V., Pollicita, S., Camplone, C., Piazza, A., Valeri, M., Famulari, A., et al. (2001) · Transplantation Proceedings · doi:10.1016/s0041-1345(00)02778-0 · Cited by 11
Ji, S., Li, L.-S., Cheng, Z., Cheng, D. R., Sun, Q., Chen, J.-S., Sha, G.-Z., & Liu, Z. (2007) · Transplantation Proceedings · doi:10.1016/j.transproceed.2006.11.016 · Cited by 10
Woodle, E. S., Hanaway, M. J., Mulgaonkar, S., Peddi, R., Harrison, G. A. J., Vandeputte, K., Fitzsimmons, W., First, R., & Holman, J. (2008) · Transplantation · doi:10.1097/01.tp.0000331765.03512.81 · Cited by 9
Rabbit Antithymocyte Globulin or Basiliximab for Induction Therapy?
Josephson, M. A. (2006) · New England Journal of Medicine · doi:10.1056/nejme068188 · Cited by 6
Holman, J., Harrison, G. A. J., Vandeputte, K., First, R., & Fitzsimmons, W. (2008) · Transplantation · doi:10.1097/01.tp.0000332232.05273.4f · Cited by 2
Cited by
Diagnosis and prevention of chronic kidney allograft loss
Nankivell, B. J., & Kuypers, D. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60699-5 · Cited by 324
Cancer in kidney transplant recipients
Au, E., Wong, G., & Chapman, J. R. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0022-6 · Cited by 262
Self-citationPolyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients
Hill, P., Cross, N. B., Barnett, A. N. R., Palmer, S. C., & Webster, A. C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004759.pub2 · Cited by 135
Self-citationMetabolic consequences of modern immunosuppressive agents in solid organ transplantation
Bamgbola, O. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816641580 · Cited by 85
37 Drugs that act on the immune system: cytokines and monoclonal antibodies
Vial, T., Descotes, J., Braun, F., & Behrend, M. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29037-8 · Cited by 3
Metadata
- Authors
- Webster, A. C., Ruster, L. P., McGee, R. G., Matheson, S. L., Higgins, G. Y., Willis, N. S., Chapman, J. R., & Craig, J. C.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2010-01-20
- Volume
- 2014
- Issue
- 5
- Pages
- CD003897-CD003897
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1962392014
- Cited by
- 268
- References
- 70
- FWCI
- 12.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.